Overview
- A NYU Langone genetic analysis published Sept. 3 used Mendelian randomization to show higher GLP1R activity is linked to about a 7% added risk of male‑pattern (androgenetic) hair loss for men already genetically predisposed.
- A University of Pennsylvania real‑world study reported in BMJ found adults treated with GLP‑1 drugs for type 2 diabetes reported hair loss more often than patients on other diabetes medicines, reinforcing clinical signals beyond anecdote.
- An NYU Pediatrics paper published Sept. 4 found prescribing of GLP‑1s to U.S. children ages 8–11 with obesity rose roughly 310‑fold from 2019 to June 2026, with 20,282 children receiving prescriptions and nearly all treated children having severe obesity or related conditions.
- GLP‑1s remain unapproved by the FDA for children under 12, and investigators across studies stress that current findings are associative or genetic proxies, call for mechanistic lab work, long‑term safety follow‑up, and careful off‑label stewardship.
- Clinicians and policymakers face a trade‑off as separate small studies show possible broader benefits of GLP‑1s (cardiometabolic and aging signals), meaning near‑term priorities include safety monitoring, equitable access policies, and research to identify who is most at risk for harms such as hair loss.